1
Cardozo Mario G, Cogan Derek, Cywin Charles Lawrence, Dahmann Georg, Disalvo Darren, Ginn John David, Prokopowicz Anthony S, Spero Denice M, Young Erick Richard Roush: 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta. Boehringer Ingelheim Pharmaceuticals, Boehringer Ingelheim Pharma & Co Kg, Cardozo Mario G, Cogan Derek, Cywin Charles Lawrence, Dahmann Georg, Disalvo Darren, Ginn John David, Prokopowicz Anthony S, Spero Denice M, Young Erick Richard Roush, RAYMOND Robert P, August 12, 2004: WO/2004/067516 (34 worldwide citation)

Disclosed are novel compounds of formula (I) wherein R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorde ...


2
Bosanac Todd, Ginn John David, Hickey Eugene Richard, Kirrane Thomas Martin, Liu Weimin, Prokopowicz Anthony S, Shih Cheng Kon, Snow Roger John, Turner Michael Robert, Wu Frank, Young Erick Richard, Schlyer Sabine K: Rho kinase inhibitors. Boehringer Ingelheim International, Boehringer Ingelheim Pharma & Co Kg, Bosanac Todd, Ginn John David, Hickey Eugene Richard, Kirrane Thomas Martin, Liu Weimin, Prokopowicz Anthony S, Shih Cheng Kon, Snow Roger John, Turner Michael Robert, Wu Frank, Young Erick Richard, Schlyer Sabine K, MORRIS Michael P, March 27, 2008: WO/2008/036540 (21 worldwide citation)

Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compos ...


3
GINN JOHN DAVID: Cxcr3 receptor antagonists. BOEHRINGER INGELHEIM INTERNATIONAL, Morris Michael P, November 4, 2010: WO/2010/126851 (12 worldwide citation)

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 to R6, A, B, X, Y and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment o ...


4

5
GINN JOHN DAVID: Cxcr3 receptor antagonists. BOEHRINGER INGELHEIM INTERNATIONAL, Morris Michael P, July 14, 2011: WO/2011/084985 (3 worldwide citation)

The present invention relates to compounds of formula I and pharmaceutically acceptable salts thereof, wherein R1 to R3, A, B, X, and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of va ...


6
GINN John David, MARSHALL Daniel Richard, SIBLEY Robert, SORCEK Ronald John, YOUNG Erick Richard Roush, ZHANG Yunlong: Inhibiteurs de la rho kinase, Rho kinase inhibitors. Boehringer Ingelheim International, GINN John David, MARSHALL Daniel Richard, SIBLEY Robert, SORCEK Ronald John, YOUNG Erick Richard Roush, ZHANG Yunlong, MORRIS Michael P, January 12, 2012: WO/2012/006202 (1 worldwide citation)

The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1 and X are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of Rho Kinase-medi ...


7
BOSANAC TODD, GINN JOHN DAVID, HICKEY EUGENE RICHARD, KIRRANE THOMAS MARTIN JR, LIU WEIMIN, PROKOPOWICZ ANTHONY S, SCHLYER SABINE K, SHIH CHENG KON, SNOW ROGER JOHN, TURNER MICHAEL ROBERT, WU FRANK, YOUNG ERICK RICHARD: Inhibiteurs de la RHO-kinase, RHO-Kinase-Hemmer, RHO kinase inhibitors. AERIE PHARMACEUTICALS, November 28, 2012: EP2526948-A1

Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-isoquinolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compo ...


8
Bosanac Todd, Ginn John David, Hickey Eugene Richard, Kirrane Thomas Martin, Liu Weimin, Prokopowicz Anthony S, Shih Cheng Kon, Snow Roger John, Turner Michael Robert, Wu Frank, Young Erick Richard, Schlyer Sabine K: Rho kinase inhibitors. Boehringer Ingelheim Int, Boehringer Ingelheim Pharma, June 17, 2009: EP2068878-A2

Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compos ...


9
Ginn John David, Sorcek Ronald John, Turner Michael Robert, Young Erick Richard Roush: Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use. Boehringer Ingelheim Int, Boehringer Ingelheim Pharma, March 4, 2009: EP2029608-A1

Disclosed are compounds of formula (I): (I) wherein R1 and R4 are defined herein, which are useful as inhibitors of the kinase activity of the I?B kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases, c ...


10